Medpace Investors Eligible to Lead Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings, Inc. for violations of securities laws.

Apr. 7, 2026 at 7:26am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a pair of reading glasses arranged on a clean, monochromatic background, conceptually representing the abstract themes of corporate litigation, financial regulations, and investor rights.A legal case against a pharmaceutical company highlights the need for transparency and accountability in the industry.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for violations of securities laws. The lawsuit covers the period from April 22, 2025 to February 9, 2026, and investors who purchased the company's securities during this time are encouraged to contact the firm to participate in the case before the June 5, 2026 deadline.

Why it matters

This lawsuit alleges that Medpace made false and misleading statements to the market, engaging in a scheme to artificially inflate its share price. The poor performance of the company throughout the class period exposed these misrepresentations, leading to investor losses.

The details

According to the complaint, Medpace violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission. The Schall Law Firm is representing investors in this class action lawsuit, which has not yet been certified.

  • The class period runs from April 22, 2025 to February 9, 2026.
  • The deadline to join the case is June 5, 2026.

The players

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Medpace Holdings, Inc.

A clinical research organization that provides clinical development services to the pharmaceutical, biotechnology, and medical device industries.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.”

— Brian Schall, Attorney, The Schall Law Firm

What’s next

The judge will decide on the class certification before the June 5, 2026 deadline for investors to join the case.

The takeaway

This lawsuit highlights the importance of transparency and accuracy in public company disclosures, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the pharmaceutical and biotech industries.